A 26% relative hazard reduction in recurrent ischemic stroke was observed (HR 0.74), with primary efficacy assessed as time to first ischemic stroke. OCEANIC-STROKE trial data show asundexian cuts ...

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

NEW ORLEANS, LA—Adding the factor XIa inhibitor asundexian (Bayer) to antiplatelet therapy tops antiplatelet therapy alone ...

The appropriate duration of dual antiplatelet therapy in patients at high risk for bleeding after the implantation of a drug-eluting coronary stent remains unclear. One month after they had undergone ...

Dual antiplatelet therapy after heart bypass surgery is not more effective than aspirin alone - and it increases the risk of excessive bleeding. This has now been shown in a study of 2,201 patients at ...

An investigational anti-clotting medication, asundexian, has demonstrated a reduction in the risk of a second ischemic ...

Abbreviated dual antiplatelet therapy after percutaneous coronary intervention using third-generation stents remained ...

Please provide your email address to receive an email when new articles are posted on . The efficacy of dual antiplatelet therapy vs. aspirin in patients with stroke was similar when given less than ...

An appropriate duration of dual antiplatelet therapy after percutaneous coronary intervention for acute myocardial infarction that has been treated with guideline-recommended complete ...

A research team has demonstrated that clopidogrel is more effective than aspirin as a long-term antiplatelet therapy in ...

The interest in dual antiplatelet therapy after valve-in-valve transcatheter aortic valve intervention stems from the higher thrombotic risk associated with reintervention for a bioprosthetic valve ...

Dental extraction is performed frequently and can be accompanied by perioperative or postoperative complications. Bleeding is among the most common and important issues to consider in the ...